Jefferies downgraded QuintilesIMS (NYSE:Q) from Buy to Hold in a statement released earlier today.
- Updated: October 19, 2016
Boasting a price of $76.33, QuintilesIMS (NYSE:Q) traded -0.52% lower on the day. With the last stock price close up 5.53% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the date range. QuintilesIMS has recorded a 50-day average of $77.97 and a two hundred day average of $71.95. Volume of trade was down over the average, with 341,695 shares of Q changing hands under the typical 1,097,420
Jefferies has downgraded QuintilesIMS (NYSE:Q) from Buy to Hold in a statement released on 10/19/2016.
On Friday October 14, 2016, Stifel Nicolaus released a statement for QuintilesIMS (NYSE:Q) bumped up the target price from $0.00 to $84.00 that suggested an upside of 0.11%.
With a total market value of $0, QuintilesIMS has price-earnings ratio of 22.83 with a one year low of $55.01 and a one year high of $81.45 .
A total of 15 equity analysts have released a research note on Q. Eight equity analysts rating the company a strong buy, nine equity analysts rating the company a buy, two equity analysts rating the company a hold, zero analysts rating the company a underperform, and finally zero analysts rating the company a sell with a 12-month price target of $76.50.
General Company Details For QuintilesIMS (NYSE:Q)
Quintiles IMS Holdings Inc, formerly Quintiles Transnational Holdings Inc., is a provider of biopharmaceutical development services and commercial outsourcing services. It is engaged in the development and commercialization of pharmaceutical therapies. Its segments include Product Development and Integrated Healthcare Services. Its Product Development segment is a contract research organization and is focused on Phase II-IV clinical trials and associated laboratory and analytical activities. The Integrated Healthcare Services segment includes commercial pharmaceutical sales and service organizations, and provides services, including commercial services, such as contract pharmaceutical sales forces, and healthcare business services for the healthcare sector, such as phase research, market access and consulting, health information analytics and technology consulting, and other healthcare solutions.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.